000177325 001__ 177325
000177325 005__ 20240229133737.0
000177325 0247_ $$2doi$$a10.1093/jncics/pkab077
000177325 0247_ $$2pmid$$apmid:34738070
000177325 0247_ $$2pmc$$apmc:PMC8561259
000177325 0247_ $$2altmetric$$aaltmetric:116761633
000177325 037__ $$aDKFZ-2021-02437
000177325 041__ $$aEnglish
000177325 082__ $$a610
000177325 1001_ $$0P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aAlwers, Elizabeth$$b0$$eFirst author$$udkfz
000177325 245__ $$aSmoking Behavior and Prognosis After Colorectal Cancer Diagnosis: A Pooled Analysis of 11 Studies.
000177325 260__ $$aOxford$$bOxford University Press$$c2021
000177325 3367_ $$2DRIVER$$aarticle
000177325 3367_ $$2DataCite$$aOutput Types/Journal article
000177325 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1636372686_2157
000177325 3367_ $$2BibTeX$$aARTICLE
000177325 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177325 3367_ $$00$$2EndNote$$aJournal Article
000177325 500__ $$a#EA:C070#LA:C070#
000177325 520__ $$aSmoking has been associated with colorectal cancer (CRC) incidence and mortality in previous studies, but current evidence on smoking in association with survival after CRC diagnosis is limited.We pooled data from 12 345 patients with stage I-IV CRC from 11 epidemiologic studies in the International Survival Analysis in Colorectal Cancer Consortium. Cox proportional hazards regression models were used to evaluate the associations of prediagnostic smoking behavior with overall, CRC-specific, and non-CRC-specific survival.Among 12 345 patients with CRC, 4379 (35.5%) died (2515 from CRC) over a median follow-up time of 7.5 years. Smoking was strongly associated with worse survival in stage I-III patients, whereas no association was observed among stage IV patients. Among stage I-III patients, clear dose-response relationships with all survival outcomes were seen for current smokers. For example, current smokers with 40 or more pack-years had statistically significantly worse overall, CRC-specific, and non-CRC-specific survival compared with never smokers (hazard ratio [HR] =1.94, 95% confidence interval [CI] =1.68 to 2.25; HR = 1.41, 95% CI = 1.12 to 1.78; and HR = 2.67, 95% CI = 2.19 to 3.26, respectively). Similar associations with all survival outcomes were observed for former smokers who had quit for less than 10 years, but only a weak association with non-CRC-specific survival was seen among former smokers who had quit for more than 10 years.This large consortium of CRC patient studies provides compelling evidence that smoking is strongly associated with worse survival of stage I-III CRC patients in a clear dose-response manner. The detrimental effect of smoking was primarily related to noncolorectal cancer events, but current heavy smoking also showed an association with CRC-specific survival.
000177325 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000177325 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177325 7001_ $$0P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aCarr, Prudence$$b1
000177325 7001_ $$aBanbury, Barbara$$b2
000177325 7001_ $$0P:(DE-He78)6c2a1ea8cce3580fe2d1c1df120a92b9$$aWalter, Viola$$b3
000177325 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b4$$udkfz
000177325 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b5$$udkfz
000177325 7001_ $$00000-0002-8813-0816$$aDrew, David A$$b6
000177325 7001_ $$00000-0002-6123-0219$$aGiovannucci, Edward$$b7
000177325 7001_ $$aNan, Hongmei$$b8
000177325 7001_ $$aBerndt, Sonja I$$b9
000177325 7001_ $$aHuang, Wen-Yi$$b10
000177325 7001_ $$00000-0001-5924-6871$$aPrizment, Anna$$b11
000177325 7001_ $$00000-0002-0918-661X$$aHayes, Richard B$$b12
000177325 7001_ $$aSakoda, Lori C$$b13
000177325 7001_ $$aWhite, Emily$$b14
000177325 7001_ $$00000-0002-9942-7797$$aLabadie, Julia$$b15
000177325 7001_ $$aSlattery, Martha$$b16
000177325 7001_ $$00000-0001-7153-2766$$aSchoen, Robert E$$b17
000177325 7001_ $$aDiergaarde, Brenda$$b18
000177325 7001_ $$00000-0002-9692-101X$$avan Guelpen, Bethany$$b19
000177325 7001_ $$00000-0002-5549-2036$$aCampbell, Peter T$$b20
000177325 7001_ $$aPeters, Ulrike$$b21
000177325 7001_ $$aChan, Andrew T$$b22
000177325 7001_ $$aNewcomb, Polly A$$b23
000177325 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b24$$udkfz
000177325 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b25$$eLast author$$udkfz
000177325 773__ $$0PERI:(DE-600)2975772-1$$a10.1093/jncics/pkab077$$gVol. 5, no. 5, p. pkab077$$n5$$ppkab077$$tJNCI cancer spectrum$$v5$$x2515-5091$$y2021
000177325 909CO $$ooai:inrepo02.dkfz.de:177325$$pVDB
000177325 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000177325 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000177325 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c2a1ea8cce3580fe2d1c1df120a92b9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000177325 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000177325 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000177325 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000177325 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b25$$kDKFZ
000177325 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000177325 9141_ $$y2021
000177325 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-11
000177325 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-11
000177325 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-11
000177325 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-11
000177325 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-09-11
000177325 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ$$d2020-09-11
000177325 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-11
000177325 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2020-09-11
000177325 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-11
000177325 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-11
000177325 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-11
000177325 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000177325 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000177325 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000177325 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x3
000177325 980__ $$ajournal
000177325 980__ $$aVDB
000177325 980__ $$aI:(DE-He78)C070-20160331
000177325 980__ $$aI:(DE-He78)C120-20160331
000177325 980__ $$aI:(DE-He78)HD01-20160331
000177325 980__ $$aI:(DE-He78)C020-20160331
000177325 980__ $$aUNRESTRICTED